Welcome to our dedicated page for Olaplex Holdings SEC filings (Ticker: OLPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Olaplex Holdings, Inc. filings document the formal disclosures of a Nasdaq-listed beauty company with common stock registered under the symbol OLPX. Recent Form 8-K reports cover results of operations and financial condition, including sales performance across professional, specialty retail, and direct-to-consumer channels and U.S. and international markets.
The filing record also documents material definitive agreements, capital-structure disclosures, shareholder voting matters, governance changes, and compensatory arrangements. Company-specific disclosures include the completed acquisition of Purvala Bioscience by an Olaplex subsidiary, board composition updates, and other material-event reporting tied to the company’s hair-care innovation and public-company obligations.
Olaplex Holdings (OLPX) reported Q3 2025 results. Net sales were $114.6 million versus $119.1 million a year ago as specialty retail and DTC softened, while professional channel sales grew. Gross margin improved to 69.1%, but higher selling, general and administrative costs—driven by a $9.3 million expense for the Purvala IPR&D asset acquisition and increased marketing and payroll—reduced operating income to $4.2 million from $28.0 million.
Net income was $11.1 million ($0.02 diluted EPS) versus $14.8 million, aided by a $9.5 million non‑cash reduction to the Tax Receivable Agreement liability related to the OBBBA. The company voluntarily repaid $300.0 million on its 2022 Term Loan Facility, lowering long‑term debt to $352.1 million and interest expense, with cash and cash equivalents at $286.4 million as of September 30, 2025.
Olaplex accrued $47.5 million for a pending settlement in the Lilien matter and recorded a $46.8 million insurance receivable. Q3 channel mix: Professional $44.5 million, Specialty retail $36.9 million, DTC $33.3 million. Shares outstanding were 667,431,776 as of September 30, 2025.
Olaplex Holdings, Inc. (OLPX) furnished an 8‑K to announce its results of operations for the third quarter ended September 30, 2025. The company disclosed that a press release with these results was issued on November 6, 2025 and is included as Exhibit 99.1.
The information under Item 2.02 is expressly stated as “furnished,” not “filed,” under the Exchange Act, and is not incorporated by reference into other filings unless specifically referenced. The filing also lists the cover page interactive data as Exhibit 104.
Olaplex Holdings, Inc. reported a material event on Form 8-K disclosing a Stock Purchase Agreement dated August 20, 2025 among Olaplex, Inc., Purvala Bioscience, Inc., the stockholders and optionholders of Purvala, and Shareholder Representative Services LLC as representative of those holders. The filing also references a press release dated August 26, 2025 and includes the cover page interactive data file embedded in the Inline XBRL document. The Form 8-K is signed on behalf of Olaplex by Amanda Baldwin, Chief Executive Officer. The filing identifies a material transaction but provides no financial terms, closing conditions, or timing details within the provided excerpt.
Tricia Glynn, a director of Olaplex Holdings, Inc. (OLPX), reported an insider acquisition on 08/13/2025. The filing shows a grant of 110,294 restricted stock units (RSUs) under the companys 2021 Equity Incentive Plan, each representing the conditional right to one share. Those RSUs vest in full on the date of Olaplexs 2026 Annual Meeting, subject to continued service. After the RSU grant, Ms. Glynn is reported to beneficially own 248,693 shares directly. The filing also discloses 499,468,771 shares held by funds and accounts managed by Advent International, L.P., where Ms. Glynn is a Managing Director; the filing includes a disclaimer limiting asserted beneficial ownership to any pecuniary interest. The Form 4 was signed by an attorney-in-fact on 08/15/2025.
Michael James White, a director of Olaplex Holdings, Inc. (OLPX), reported an acquisition of 110,294 restricted stock units (RSUs) on 08/13/2025 at a reported price of $0.00. Each RSU represents the conditional right to one share and the RSUs will vest in full on the date of the issuer's 2026 annual meeting, subject to continued service. Following the grant, Mr. White directly beneficially owns 248,693 shares. The report also discloses that various funds and accounts managed by Advent International hold 499,468,771 shares, and Mr. White is identified as a Principal of Advent, with a disclaimer that he disclaims beneficial ownership except to the extent of any pecuniary interest.
David M. Mussaffer, a director of Olaplex Holdings, Inc. (OLPX), reported receipt of 110,294 restricted stock units (RSUs) on 08/13/2025 under the Issuer's 2021 Equity Incentive Plan. Each RSU converts to one share and will vest in full on the date of the Issuer's 2026 Annual Meeting, subject to continued service. The transaction is recorded at a $0.00 price. Following the reported award, the filing shows 248,693 shares beneficially owned directly and 499,468,771 shares held indirectly by funds/accounts managed by Advent International, L.P., where Mussaffer is Chairman and Managing Partner. The report was signed by an attorney-in-fact on 08/15/2025.
Catherine Dunleavy, Chief Operating Officer and Chief Financial Officer of Olaplex Holdings, Inc. (OLPX), reported the sale of 101,798 shares of Olaplex common stock on 08/14/2025 as a sell-to-cover transaction to satisfy tax withholding on vested restricted stock units. The weighted-average sale price was reported as $1.40. After the disposition, Ms. Dunleavy beneficially owns 1,966,848 shares, reported as direct ownership. The Form 4 was signed by an attorney-in-fact on 08/15/2025. The filing states the shares were sold in multiple transactions at prices ranging from $1.4001 to $1.4004.
Emily White, a director of Olaplex Holdings, Inc. (OLPX), was granted 110,294 restricted stock units (RSUs) on 08/12/2025 under the 2021 Equity Incentive Plan. Each RSU converts to one share and will vest in full at the company’s 2026 Annual Meeting only if Ms. White remains in service. The filing also reports sizable indirect beneficial ownership: 23,476,117 shares held by Anthos Capital IV, L.P., 148,064 shares held by Anthos Tribe, L.P., and 138,399 shares held by Anthos Management LP; Ms. White disclaims beneficial ownership except for any pecuniary interest. The form was signed by an attorney-in-fact on 08/14/2025.
Martha A. Morfitt, a director of Olaplex Holdings, Inc. (OLPX), was granted 110,294 restricted stock units (RSUs) on 08/12/2025. Each RSU converts to one share of common stock and the grant was reported with a $0 price. After the award the reporting person beneficially owned 402,833 shares directly and the reporting person’s spouse beneficially owned 9,000 shares indirectly. The RSUs will vest in full on the date of the issuer’s 2026 Annual Meeting of Stockholders, conditioned on the reporting person’s continued service through that date. The Form 4 was signed by attorney-in-fact John Duffy on 08/14/2025.
Olaplex Holdings insider grant of restricted stock units to a director. Director Jerome Griffith was granted 110,294 restricted stock units (RSUs) of Olaplex common stock on 08/12/2025 at no cash price. Each RSU represents a conditional right to one share and the award will vest in full on the date of the company’s 2026 Annual Meeting of Stockholders, subject to continued service. After the grant, the reporting person beneficially owns 110,294 shares on a direct basis related to these RSUs. The filing states the award was made under the Issuer’s 2021 Equity Incentive Plan.